Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics

Joseph G. Crompton, Madhusudhanan Sukumar, Rahul Roychoudhuri, David Clever, Alena Gros, Robert L. Eil, Eric Tran, Ken Ichi Hanada, Zhiya Yu, Douglas C. Palmer, Sid P. Kerkar, Ryan D. Michalek, Trevor Upham, Anthony Leonardi, Nicolas Acquavella, Ena Wang, Francesco M. Marincola, Luca Gattinoni, Pawel Muranski, Mark S. SundrudChristopher A. Klebanoff, Steven A. Rosenberg, Douglas T. Fearon, Nicholas P. Restifo

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) results in complete regression of advanced cancer in some patients, but the efficacy of this potentially curative therapy may be limited by poor persistence of TIL after adoptive transfer. Pharmacologic inhibition of the serine/ threonine kinase Akt has recently been shown to promote immunologic memory in virus-specific murine models, but whether this approach enhances features of memory (e.g., long-term persistence) in TIL that are characteristically exhausted and senescent is not established. Here, we show that pharmacologic inhibition of Akt enables expansion of TIL with the transcriptional, metabolic, and functional properties characteristic of memory T cells. Consequently, Akt inhibition results in enhanced persistence of TIL after adoptive transfer into an immunodeficient animal model and augments antitumor immunity of CD8 T cells in a mouse model of cell-based immunotherapy. Pharmacologic inhibition of Akt represents a novel immunometabolomic approach to enhance the persistence of antitumor T cells and improve the efficacy of cell-based immunotherapy for metastatic cancer.

Original languageEnglish
Pages (from-to)296-305
Number of pages10
JournalCancer Research
Volume75
Issue number2
DOIs
Publication statusPublished - 8 Aug 2015

Fingerprint

Tumor-Infiltrating Lymphocytes
Lymphocytes
Adoptive Transfer
Neoplasms
T-Lymphocytes
Immunotherapy
Immunologic Memory
Long-Term Memory
Protein-Serine-Threonine Kinases
Cell- and Tissue-Based Therapy
Immunity
Animal Models
Inhibition (Psychology)
Viruses

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Crompton, J. G., Sukumar, M., Roychoudhuri, R., Clever, D., Gros, A., Eil, R. L., ... Restifo, N. P. (2015). Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Research, 75(2), 296-305. https://doi.org/10.1158/0008-5472.CAN-14-2277

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. / Crompton, Joseph G.; Sukumar, Madhusudhanan; Roychoudhuri, Rahul; Clever, David; Gros, Alena; Eil, Robert L.; Tran, Eric; Hanada, Ken Ichi; Yu, Zhiya; Palmer, Douglas C.; Kerkar, Sid P.; Michalek, Ryan D.; Upham, Trevor; Leonardi, Anthony; Acquavella, Nicolas; Wang, Ena; Marincola, Francesco M.; Gattinoni, Luca; Muranski, Pawel; Sundrud, Mark S.; Klebanoff, Christopher A.; Rosenberg, Steven A.; Fearon, Douglas T.; Restifo, Nicholas P.

In: Cancer Research, Vol. 75, No. 2, 08.08.2015, p. 296-305.

Research output: Contribution to journalArticle

Crompton, JG, Sukumar, M, Roychoudhuri, R, Clever, D, Gros, A, Eil, RL, Tran, E, Hanada, KI, Yu, Z, Palmer, DC, Kerkar, SP, Michalek, RD, Upham, T, Leonardi, A, Acquavella, N, Wang, E, Marincola, FM, Gattinoni, L, Muranski, P, Sundrud, MS, Klebanoff, CA, Rosenberg, SA, Fearon, DT & Restifo, NP 2015, 'Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics', Cancer Research, vol. 75, no. 2, pp. 296-305. https://doi.org/10.1158/0008-5472.CAN-14-2277
Crompton, Joseph G. ; Sukumar, Madhusudhanan ; Roychoudhuri, Rahul ; Clever, David ; Gros, Alena ; Eil, Robert L. ; Tran, Eric ; Hanada, Ken Ichi ; Yu, Zhiya ; Palmer, Douglas C. ; Kerkar, Sid P. ; Michalek, Ryan D. ; Upham, Trevor ; Leonardi, Anthony ; Acquavella, Nicolas ; Wang, Ena ; Marincola, Francesco M. ; Gattinoni, Luca ; Muranski, Pawel ; Sundrud, Mark S. ; Klebanoff, Christopher A. ; Rosenberg, Steven A. ; Fearon, Douglas T. ; Restifo, Nicholas P. / Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. In: Cancer Research. 2015 ; Vol. 75, No. 2. pp. 296-305.
@article{aa692649e43649669b6bda2fc60c192b,
title = "Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics",
abstract = "Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) results in complete regression of advanced cancer in some patients, but the efficacy of this potentially curative therapy may be limited by poor persistence of TIL after adoptive transfer. Pharmacologic inhibition of the serine/ threonine kinase Akt has recently been shown to promote immunologic memory in virus-specific murine models, but whether this approach enhances features of memory (e.g., long-term persistence) in TIL that are characteristically exhausted and senescent is not established. Here, we show that pharmacologic inhibition of Akt enables expansion of TIL with the transcriptional, metabolic, and functional properties characteristic of memory T cells. Consequently, Akt inhibition results in enhanced persistence of TIL after adoptive transfer into an immunodeficient animal model and augments antitumor immunity of CD8 T cells in a mouse model of cell-based immunotherapy. Pharmacologic inhibition of Akt represents a novel immunometabolomic approach to enhance the persistence of antitumor T cells and improve the efficacy of cell-based immunotherapy for metastatic cancer.",
author = "Crompton, {Joseph G.} and Madhusudhanan Sukumar and Rahul Roychoudhuri and David Clever and Alena Gros and Eil, {Robert L.} and Eric Tran and Hanada, {Ken Ichi} and Zhiya Yu and Palmer, {Douglas C.} and Kerkar, {Sid P.} and Michalek, {Ryan D.} and Trevor Upham and Anthony Leonardi and Nicolas Acquavella and Ena Wang and Marincola, {Francesco M.} and Luca Gattinoni and Pawel Muranski and Sundrud, {Mark S.} and Klebanoff, {Christopher A.} and Rosenberg, {Steven A.} and Fearon, {Douglas T.} and Restifo, {Nicholas P.}",
year = "2015",
month = "8",
day = "8",
doi = "10.1158/0008-5472.CAN-14-2277",
language = "English",
volume = "75",
pages = "296--305",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics

AU - Crompton, Joseph G.

AU - Sukumar, Madhusudhanan

AU - Roychoudhuri, Rahul

AU - Clever, David

AU - Gros, Alena

AU - Eil, Robert L.

AU - Tran, Eric

AU - Hanada, Ken Ichi

AU - Yu, Zhiya

AU - Palmer, Douglas C.

AU - Kerkar, Sid P.

AU - Michalek, Ryan D.

AU - Upham, Trevor

AU - Leonardi, Anthony

AU - Acquavella, Nicolas

AU - Wang, Ena

AU - Marincola, Francesco M.

AU - Gattinoni, Luca

AU - Muranski, Pawel

AU - Sundrud, Mark S.

AU - Klebanoff, Christopher A.

AU - Rosenberg, Steven A.

AU - Fearon, Douglas T.

AU - Restifo, Nicholas P.

PY - 2015/8/8

Y1 - 2015/8/8

N2 - Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) results in complete regression of advanced cancer in some patients, but the efficacy of this potentially curative therapy may be limited by poor persistence of TIL after adoptive transfer. Pharmacologic inhibition of the serine/ threonine kinase Akt has recently been shown to promote immunologic memory in virus-specific murine models, but whether this approach enhances features of memory (e.g., long-term persistence) in TIL that are characteristically exhausted and senescent is not established. Here, we show that pharmacologic inhibition of Akt enables expansion of TIL with the transcriptional, metabolic, and functional properties characteristic of memory T cells. Consequently, Akt inhibition results in enhanced persistence of TIL after adoptive transfer into an immunodeficient animal model and augments antitumor immunity of CD8 T cells in a mouse model of cell-based immunotherapy. Pharmacologic inhibition of Akt represents a novel immunometabolomic approach to enhance the persistence of antitumor T cells and improve the efficacy of cell-based immunotherapy for metastatic cancer.

AB - Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) results in complete regression of advanced cancer in some patients, but the efficacy of this potentially curative therapy may be limited by poor persistence of TIL after adoptive transfer. Pharmacologic inhibition of the serine/ threonine kinase Akt has recently been shown to promote immunologic memory in virus-specific murine models, but whether this approach enhances features of memory (e.g., long-term persistence) in TIL that are characteristically exhausted and senescent is not established. Here, we show that pharmacologic inhibition of Akt enables expansion of TIL with the transcriptional, metabolic, and functional properties characteristic of memory T cells. Consequently, Akt inhibition results in enhanced persistence of TIL after adoptive transfer into an immunodeficient animal model and augments antitumor immunity of CD8 T cells in a mouse model of cell-based immunotherapy. Pharmacologic inhibition of Akt represents a novel immunometabolomic approach to enhance the persistence of antitumor T cells and improve the efficacy of cell-based immunotherapy for metastatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84921044688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921044688&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-2277

DO - 10.1158/0008-5472.CAN-14-2277

M3 - Article

C2 - 25432172

AN - SCOPUS:84921044688

VL - 75

SP - 296

EP - 305

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 2

ER -